Title of study


DZNE Cognitive Impairment Longitudinal Study

Acronym for cohort


DECI

Name of Principal Investigator - Title


Prof

Name of Principal Investigator - First name


Frank

Name of Principal Investigator - Last name


Jessen

Address of institution -Institution


DZNE

Address of institution - Street address


Sigmund-Freud-Str. 25

Address of institution - City


Bonn

Address of institution - Postcode


53105

Country


Germany

Website


www.dzne.de

Contact email


[email protected]

Funding source


Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?


Alzheimer's disease and other dementias

Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)


To build up a cohort of pre-MCI and MCI patient that allow to identify early markers of dementia

Q2b. What distinguishes this case-control study from other studies?


Q3a. i) Number of publications that involve use of your cohort to date


0

Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)


Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available


Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study


Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:


70

Q4a. Study criteria: what is the age range of participants at recruitment? To:


until death

Q4b. Study criteria: what are the inclusion criteria?


Subjective memory impairment or MCI

Q4c. Study criteria: what are the exclusion criteria?


Manifest dementia

Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?


1-1,000

Q5b. What is the expected number of control participants?


200-500

Q6a. Please describe what measures are used to characterise participants


Neuropsychology, MRI, amyloid-PET, CSF

Q6b. Are there additional measures for participants with the clinical disorder?


Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?


Yes

If YES please specify


Manifestation of dementia

Q7. What is the study design?


Prospective cohort

Q8. Are your cases matched by


Age||Sex

Q9a. Does your study includes a specialised subset of control participants?


No

Q9b. If your study includes a specialised subset of control participants please describe


Q10a. Is data collection for this study


At the planning stage

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?


Yes - intend to apply for funding

Q11. Are data collected


Q12. Is there a system in place to enable re-contact with patients for future studies?


Q13a. Please give information on data stored in a database (1)


% Available


Q13a. Please give information on data stored in a database (2)


% Available


Q13a. Please give information on data stored in a database (3)


% Available


Q13a. Please give information on data stored in a database (4)


% Available


Q13a. Please give information on data stored in a database (5)


% Available


Please specify language used


% Available


Q13b. Please give information on how data is held as individual records


% Available


Q14a. Are data available to other groups?


No

Q14b. If data is available to other groups what is the access policy/mechanisms for access?


Q15. What data sharing policy is specified as a condition of use?


No requirement to make data publicly available

Q16a. Are tissues/samples/DNA available to other groups?


No

Q16b i) If yes, please describe below


Q16b. ii) In what form are tissues/samples/DNA supplied?


Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?


Q17. Is information on biological characteristics available to other groups?


No

Export as PDF